Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 26, 2025
CRISPR Therapeutics Announces Transition of Chief Operating Officer
GlobeNewswire
·
March 26, 2025
ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, …
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
GlobeNewswire
·
March 26, 2025
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 …
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
March 26, 2025
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial …
Inventiva reports its 2024 full year results and provides a business update
GlobeNewswire
·
March 26, 2025
Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 million Last patient screened in the …
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité
GlobeNewswire
·
March 26, 2025
Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024 Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024 Levée d’un produit brut de 116 millions d’euros dans le cadre de la première tranche du Financement Structuré …
Heartflow Closes $98 Million Convertible Notes Financing
GlobeNewswire
·
March 26, 2025
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced additional investments in the company of approximately $98 million through the sale and issuance of …
Mitolyn Reviews (URGENT CLINICAL REPORT) Real Users Expose the Truth About Its Metabolism-Boosting Claims
GlobeNewswire
·
March 26, 2025
SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Mitolyn When it comes to weight loss supplements, consumer experiences and real-world results matter more than marketing hype. With Mitolyn gaining rapid attention, people are asking the same questions: Does …
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
GlobeNewswire
·
March 26, 2025
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that …
Protecting 2SLGBTQ+ Seniors in Ontario: Rainbow Faith and Freedom Launches Crucial Initiative
GlobeNewswire
·
March 26, 2025
TORONTO, March 26, 2025 (GLOBE NEWSWIRE) -- Rainbow Faith and Freedom (RFF) has launched an important initiative to address the challenges faced by 2SLGBTQ+ seniors living in senior care facilities across Ontario. This project seeks to ensure that queer …
Mitolyn Reviews (DOCTOR INVESTIGATES) Can It Really Boost Energy, Burn Fat & Support Mitochondria Naturally?
GlobeNewswire
·
March 26, 2025
Seattle, March 26, 2025 (GLOBE NEWSWIRE) -- Mitolyn With the massive flood of weight loss and energy-boosting supplements on the market, it’s easy to be skeptical of Mitolyn. Is it truly a science-backed solution for metabolism and fat loss, or just …
New Book Navigating Inflammatory Bowel Disease – A Six-Week Blueprint for Better Gut Health
EIN Presswire
·
March 26, 2025
Empowers Patients and Caregivers ST PETERSBURG, FL, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- New Book Navigating Inflammatory Bowel Disease – A Six-Week Blueprint for Better Gut Health Empowers Patients and Caregivers Today marks the launch …
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
GlobeNewswire
·
March 26, 2025
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today …
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights
GlobeNewswire
·
March 26, 2025
EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However, findings from Spherix’s fifth annual Patient Chart Dynamix™ : IgA …
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 26, 2025
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million1 as of December 31, 2024, ensuring financial visibility until Q1 2027 Three strategic agreements signed …
OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement
GlobeNewswire
·
March 26, 2025
OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement Revenu total de 83,4 millions d’euros et position de trésorerie1 de 64,2 millions d’euros au 31 décembre 2024, assurant une visibilité …
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
GlobeNewswire
·
March 26, 2025
Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its registration …
Valneva renouvelle son contrat de placement (Sales Agreement) dans le cadre de son programme « At-the-Market (ATM) » existant
GlobeNewswire
·
March 26, 2025
Saint-Herblain (France), 26 mars 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce aujourd’hui qu’elle a déposé auprès de la U.S. Securities and Exchange Commission (« …
GUERBET : 2024 full-year results.
GlobeNewswire
·
March 26, 2025
2024 full-year results Very strong business momentum Full-year revenue: €841.1 million, up 9.0% at constant exchange rates (CER)1 and on a like-for-like basis2 Strong momentum in the Americas (+20.5% at CER and like-for-like), Asia (+10.1%) and EMEA …
GUERBET : Résultats annuels 2024.
GlobeNewswire
·
March 26, 2025
Résultats annuels 2024 Activité très dynamique Chiffre d’affaires annuel : 841,1 M€, affichant une progression de 9,0% à taux de change constant (TCC)1 et périmètre comparable2 Une dynamique soutenue dans la zone Amériques (+20,5% à TCC et périmètre …
PrimeBiome Reviews - Is it Worth Buying? Prime Biome Gummies Ingredients, Side Effects, and Investigative Report
GlobeNewswire
·
March 26, 2025
ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- PrimeBioMe is a natural dietary supplement designed to support gut health, improve digestion, and enhance skin appearance. It is made with a blend of plant-based ingredients, it helps balance the gut …